In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Safety and efficacy of Brilinta (Ticagrelor) for endovascular procedures.

    Final Number:
    1411

    Authors:
    Philipp Taussky MD; William D. Freeman MD; Rabih G. Tawk MD; Ricardo Alexandre Hanel

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: The endovascular use of intra- and extra-cranial stents requires dual anti-platelet therapy, traditionally by Aspirin and Plavix. About one third of patients appear to be non responders to Plavix and will need alternative treatment options. Brilinta is a new reversible blocker of adenosine diphosphate (ADP) receptor of subtype P2Y12. The use of Brilinta for endovascular procedures as an alternative to Plavix has not been previously studied.

    Methods: We reviewed our cerebrovascular database for all patients who were non responders to Plavix despite repeat Plavix loading dose of at least 600 mg as measured by P2Y12 levels and who were then administered Brilinta.

    Results: We report the use of Brilinta in 8 patients who were none responders to Plavix according to measured P2Y12 levels. 6 patients were male, 2 female with a median age of 68 yrs (range 36-81). All patients received loading doses of at least 600 mg of Plavix and showed P2Y12 levels below 10% prior to Brilinta administration. Patients were loaded with 180mg of Brilinta and all showed an initial P2Y12 response above 90%. 7 patients underwent extracranial or intracranial stenting and one patient underwent treatment by Pipeline embolization device. No patient experienced any adverse effects in the postoperative period related to the use of Brilinta.

    Conclusions: Brilinta offers a safe and effective alternative to patients who are non-responders to Plavix. All our patients showed an immediate response to Brilinta after loading dose with 180 mg resulting in P2Y12 levels above 90%. While no adverse effects were noted further studies are needed to validate the use of Brilinta for endovascular procedures.

    Patient Care: Our research shows the safety and efficacy of Brilinta for patients who are non-responders to Plavix and who are in need of extra- or intra-cranial stenting.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1. Describe the indication of dual anti platelet therapy 2.Management and measurements of anti platelet therapies 3. Pharmacokinetics of anti platelet therapies.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy